TON - March/April 2011, VOL 4, NO 2

Extravasation is always a risk when administering medicines intravenously. This is when the infused drug infiltrates the tissue surrounding the injection site. The resulting injury can range from mild to lifethreatening, depending on whether the drug involved is classified as an irritant or a vesicant.

The Infusion Nurses Society (INS) defines a vesicant as “an agent capable of causing injury when it escapes from the intended vascular pathway into the surrounding tissue.”1

Read More ›

A call came from a nurse attending to 3 patients in the infusion clinic. One patient had received a full dose of doxorubicin (60 mg/m2) via the vein in the dorsum of her hand. Afterward, the nurse detected a trace of blood in the infusion tube. While administering post-dose hydration, she noticed that the patient’s hand was completely swollen.

Read More ›

Contra Costa Regional Medical Center is a public hospital with 167 beds. Despite our hospital’s cost-conscious approach to formulary management, it was one of the first in the area to add the dexrazoxane for injection (Totect) emergency treatment kit to its formulary. This addition predated the On cology Nursing Society guidelines on managing anthracycline extravasation and followed a long process involving presentations to 4 hospital committees.

Read More ›


Patients with inoperable metastatic melanoma now have another treatment option as ipilimumab becomes the second immunotherapy drug approved by the US Food and Drug Administration (FDA) for the treatment of cancer. Read More ›

Recruiting adults with cancer to take part in clinical trials is an ongoing challenge in the United States, but the growing number of studies for targeted therapeutics and the positive news emerging from these studies might help turn that around. Read More ›

The somatostatin analog lanreotide (Somatuline) reduced the frequency of vomiting for patients with inoperable malignant bowel obstruction (MBO) in what presenter Pascale Mariani, MD, at the Institut Curie in Paris, France, called the first randomized, doubleblind, placebo-controlled study on palliative care in this patient population. Read More ›

Page 4 of 4


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: